Press release
Uveitis Market Forecasted to Reach USD 4.1 Billion by 2034
Uveitis
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72295
The global uveitis market is expanding as the prevalence of autoimmune diseases rises, and as new biologic therapies, corticosteroid-sparing treatments, and targeted immunotherapies offer improved outcomes. Early detection and tailored treatment approaches are essential to managing this potentially sight-threatening condition.
Market Overview
• Market Size (2024): USD 1.9 billion
• Forecast (2034): USD 4.1 billion
• CAGR (2025-2034): 7.9%
Key Highlights:
• Growing incidence of autoimmune diseases and inflammatory disorders driving market demand.
• Increasing adoption of biologic therapies (TNF inhibitors, IL-6 inhibitors) for systemic uveitis treatment.
• Rising use of intraocular steroids and biologic injections for managing ocular inflammation.
• Expanding access to AI-powered diagnostic tools for early detection and monitoring.
Segmentation Analysis
By Treatment Type:
• Biologic Therapies (fastest-growing segment)
o Anti-TNF agents (adalimumab, infliximab)
o Anti-IL agents (tocilizumab, secukinumab)
• Corticosteroids
o Intravitreal Injections (e.g., dexamethasone)
o Oral/Topical Steroids
• Immunosuppressants
o Methotrexate
o Azathioprine
o Mycophenolate mofetil
• Laser Therapy
o Panretinal Photocoagulation
• Surgical Interventions
o Vitrectomy (for advanced retinal complications)
By Disease Type:
• Anterior Uveitis (largest share)
• Intermediate Uveitis
• Posterior Uveitis
• Panuveitis (all layers of the uvea)
By End Use:
• Hospitals & Specialty Eye Clinics
• Ambulatory Surgical Centers
• Academic & Research Institutes
• Retail & Online Pharmacies
Segmentation Summary:
Biologic therapies are the fastest-growing category, but corticosteroids remain the cornerstone for acute flare-ups. Uveitis treatments are increasingly tailored to the disease type, with more specific biologics targeting the underlying inflammatory pathways.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72295/uveitis-market
Regional Analysis
North America
• Largest market (~42% share in 2024).
• High adoption of biologic therapies, with strong insurance coverage for ocular treatments.
• Growing awareness of uveitis and systemic inflammatory diseases.
Europe
• ~31% share.
• Germany, UK, and France leading adoption of biologic therapies and specialized uveitis care.
• EMA-supported clinical trials for uveitis therapies.
Asia-Pacific
• Fastest-growing region, CAGR ~9.2%.
• Increasing prevalence of autoimmune diseases and expanding access to biologics in China, Japan, and India.
• Growing healthcare infrastructure and patient awareness in Southeast Asia.
Latin America
• Brazil and Mexico improving access to systemic therapies and surgical treatments.
Middle East & Africa
• GCC countries investing in advanced ophthalmic and immunology services.
• Significant unmet need in Sub-Saharan Africa due to limited specialist availability and diagnostic infrastructure.
Regional Summary:
North America and Europe lead in biologic adoption, while Asia-Pacific is poised for rapid growth, driven by expanding healthcare access and rising autoimmune disease prevalence.
Market Dynamics
Key Growth Drivers:
• Increasing prevalence of autoimmune disorders and infections (e.g., sarcoidosis, rheumatoid arthritis).
• Adoption of TNF inhibitors and IL-6 inhibitors in treating systemic uveitis.
• Improved diagnostic tools for early-stage detection and monitoring.
• Expanding healthcare access and precision medicine in ophthalmology.
Key Challenges:
• High cost of biologics and corticosteroid injections.
• Risk of side effects (glaucoma, cataracts) from prolonged corticosteroid use.
• Delayed diagnosis and underdiagnosis of posterior and panuveitis.
• Limited access to advanced therapies in low-income countries.
Latest Trends:
• Increasing use of sustained-release corticosteroid implants for long-term management.
• Rising clinical interest in gene therapies and cell-based treatments for retinal regeneration.
• AI-based diagnostics and tele-ophthalmology playing a growing role in screening and early detection.
• Ongoing clinical trials for next-generation biologics targeting the IL-23, IL-17 pathways.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72295
Competitor Analysis
Major Players in the Market:
• AbbVie Inc. (Humira - adalimumab, Rinvoq)
• Novartis AG (Cosentyx - secukinumab)
• Regeneron Pharmaceuticals, Inc. (Eylea - aflibercept)
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Vision (REMICADE - infliximab)
• Allergan (Dexamethasone intravitreal implant)
• Santen Pharmaceutical Co., Ltd.
• Bausch + Lomb
• Alimera Sciences
• Eyepoint Pharmaceuticals, Inc.
Competitive Summary:
AbbVie and Novartis dominate biologics, while Regeneron and Johnson & Johnson drive systemic uveitis therapies. Santen, Bausch + Lomb, and Alimera Sciences provide corticosteroid options, with Alimera leading in sustained-release implant therapy. The market is increasingly focused on targeted biologics and personalized treatments.
Conclusion
The Uveitis Market, valued at USD 1.9 billion in 2024, is projected to reach USD 4.1 billion by 2034, growing at a CAGR of 7.9%.
Key Takeaways:
• Biologic therapies (TNF inhibitors, IL-6 inhibitors) are reshaping uveitis treatment.
• North America and Europe are leading, but Asia-Pacific shows the highest growth potential.
• Precision medicine, AI-based diagnostics, and gene therapy will drive the future.
• Increased awareness, screening programs, and better accessibility will help reduce vision loss globally.
Over the next decade, the uveitis market will evolve from broad immunosuppression to targeted biologics and advanced ocular treatments, significantly improving patient outcomes and reducing complications.
This report is also available in the following languages : Japanese (ぶどう膜炎市場), Korean (포도막염 시장), Chinese (葡萄膜炎市场), French (Marché de l'uvéite), German (Uveitis-Markt), and Italian (Mercato dell'uveite), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72295/uveitis-market#request-a-sample
Our More Reports:
Modular Pharmaceutical Construction Market
https://exactitudeconsultancy.com/reports/73157/modular-pharmaceutical-construction-market
3D Cell Culture Market
https://exactitudeconsultancy.com/reports/73158/3d-cell-culture-market
Antibody Humanization Market
https://exactitudeconsultancy.com/reports/73159/antibody-humanization-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uveitis Market Forecasted to Reach USD 4.1 Billion by 2034 here
News-ID: 4195918 • Views: …
More Releases from Exactitude Consultancy
North America ERCP and PTC Devices Market Expected to Grow at 8.1% CAGR
Introduction
Biliary and pancreatic disorders such as gallstones, strictures, bile duct cancers, and pancreatitis represent significant healthcare challenges in North America. Diagnostic and therapeutic interventions like Endoscopic Retrograde Cholangiopancreatography (ERCP) and Percutaneous Transhepatic Cholangiography (PTC) have become indispensable in managing these conditions.
Both procedures require advanced devices - including endoscopes, catheters, guidewires, stents, and balloon dilators - designed for precision and minimally invasive treatment. Rising prevalence of gastrointestinal (GI) cancers, an aging…
North America Gastric Bands and Balloons Market Projected to Grow at 7.5% CAGR
Introduction
Obesity has become a critical public health challenge in North America, with rising prevalence rates leading to increased risks of diabetes, cardiovascular disease, and other chronic conditions. As healthcare systems focus on preventive care and weight management, demand for bariatric interventions has surged. Among the available options, gastric bands and balloons have gained popularity as effective, minimally invasive treatments for obesity.
These devices provide an alternative to traditional bariatric surgery by…
Glaucoma Market Forecasted to Reach USD 6.9 Billion by 2034
Glaucoma is a group of eye diseases characterized by optic nerve damage, often due to increased intraocular pressure (IOP). It is a leading cause of irreversible blindness, particularly among elderly populations. The two most common types are primary open-angle glaucoma (POAG) and angle-closure glaucoma, with POAG accounting for over 70% of glaucoma cases.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72297
With the growing burden of aging populations, rising prevalence…
Retinitis Pigmentosa Market Forecasted to Reach USD 4.5 Billion by 2034
Retinitis pigmentosa (RP) is a genetically heterogeneous group of inherited retinal diseases that cause progressive degeneration of the retina, primarily affecting the photoreceptor cells. It leads to progressive vision loss, starting with night blindness and peripheral vision loss and eventually advancing to central vision loss. RP is a leading cause of blindness in young adults, with a global prevalence of 1 in 4,000 individuals.
Download Full PDF Sample Copy of Market…
More Releases for Uveitis
Uveitis Market : An Overview Report
Introduction:
Uveitis is an inflammatory condition affecting the uvea, the middle layer of the eye. It can lead to vision impairment or even blindness if left untreated. Uveitis is categorized into different types, including anterior, intermediate, posterior, and panuveitis, depending on the part of the eye affected. The condition can be caused by infections, autoimmune diseases, or trauma. With increasing cases of autoimmune disorders and infectious diseases, the prevalence of uveitis…
Uveitis Treatment Market Size, Share | Trend 2030
Exclusive Report by Ameco Research: Uveitis Treatment Market Size Projected to Reach USD 2 Billion by 2030, Growing at 6% CAGR
Ameco Research is proud to announce the launch of its latest market research report, Uveitis Treatment Market. This comprehensive report provides in-depth analysis and insights into the current market trends and future projections in the Industry/Market Segment. Ameco Research has been at the forefront of providing quality market research…
Uveitis - Drug Pipeline Landscape, 2022
New York, Global Insight Services have recently published a report on Uveitis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Uveitis is an inflammation of the eye which damages the part of the eye called the uvea and affects other parts of the eyes which causes pain to the eyes. There are 4 types of…
Uveitis - Drug Pipeline Landscape, 2022
Global Insight Services have recently published a report on Uveitis - Drug Pipeline Landscape. The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration.
Uveitis is an inflammation of the eye which damages the part of the eye called the uvea and affects other parts of the eyes which causes pain to the eyes. There are 4 types of uveitis based…
Japan Industry Statistics of Uveitis Treatment
Global Uveitis Treatment Market: Overview
Uveitis, an autoimmune eye disease, is considered rare for just around 38 in 100,000 people are afflicted by it. Because of this, it is often overlooked. Patients afflicted by uveitis are often referred to an expert after much delay on account of less awareness about the eye malady. This delays timely diagnosis and results in irreversible damage to various ocular structures.
Read Report Overview: https://www.transparencymarketresearch.com/uveitis-treatment-market.html
As per Cochrane,…
Uveitis Treatment Market Analysis of Top industry Scenario
Global Uveitis Treatment Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables).
According to a new report published by Allied Market Research, titled, "Uveitis Treatment Market by Drug Class (Anti-inflammatory, Antimicrobial Drugs, Immunotherapy &…
